Atlas Trials

Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic Leukemia

Clinical trial NCT02767934 · TERMINATED

Trial details

NCT number
NCT02767934
Sponsor
University of Washington
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
B Acute Lymphoblastic LeukemiaMinimal Residual DiseaseRecurrent Acute Lymphoblastic LeukemiaT Acute Lymphoblastic Leukemia
Start date
2017-01-13
Primary completion
2019-07-31
Enrollment
12

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.